Posted by Michael Wonder on 09 Jan 2020
Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD
9 January 2020 - Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-ALD and Friedreich’s ataxia.
Minoryx Therapeutics today announces that its lead drug candidate leriglitazone (MIN-102) has been granted fast track designation by the US FDA for the treatment of all forms of X-linked adrenoleukodystrophy, including adrenomyeloneuropathy and childhood cerebral ALD.
